42
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 1.9 Impact Factor I 5.9 CiteScore I 0.648 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      The Bayer Activities of Daily Living Scale (B-ADL)

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Bayer Activities of Daily Living Scale (B-ADL) has been developed on an international basis to assess deficits in the performance of everyday activities. The scale’s main target group is community dwelling patients who suffer mild cognitive impairment or mild-to-moderate dementia. It comprises 25 items and takes the form of a questionnaire to be completed by a caregiver or other informant sufficiently familiar with the patient. Statistical, clinical and domain-related criteria were used to select items from among a large number of activities of daily living (ADL) questions field tested in pilot studies in the USA, Germany, UK, Russia and Greece. The items included in the B-ADL have been chosen for their sensitivity to cognitive impairment, simplicity of concept, international applicability and their relevance to patients coping with the demands of everyday life. The scale uses items which reflect a wide range of domains. On account of its brevity, it is thought especially suitable for application within a GP and primary care context for both screening a patient’s ADL capacities as well as for documentation of treatment effects and the progress of dementia. This paper focuses on a description of the scale and its application.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: not found
          • Article: not found

          The Use of Clinical Experience to Stage the Severity of Functional Impairments in Alzheimer's Disease

            Bookmark

            Author and article information

            Journal
            DEM
            Dement Geriatr Cogn Disord
            10.1159/issn.1420-8008
            Dementia and Geriatric Cognitive Disorders
            S. Karger AG
            978-3-8055-6728-2
            978-3-318-00332-1
            1420-8008
            1421-9824
            1998
            July 1998
            15 July 1998
            : 9
            : Suppl 2
            : 20-26
            Affiliations
            a Human Psychopharmacology Research Unit, University of Surrey, UK; b Psychiatric University Hospital Erlangen, c Bayer AG, Leverkusen, Germany
            Article
            51195 Dement Geriatr Cogn Disord 1998;9(suppl 2):20–26
            10.1159/000051195
            9718231
            5a698284-4c2a-47d6-9068-1ed9fb33e3de
            © 1998 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            History
            Page count
            Pages: 7
            Categories
            Paper

            Geriatric medicine,Neurology,Cardiovascular Medicine,Neurosciences,Clinical Psychology & Psychiatry,Public health
            B-ADL,Mild cognitive impairment,Therapy evaluation,Vascular dementia,Dementia screening,Alzheimer’s disease,Activities of daily living

            Comments

            Comment on this article